Product Description
GBC-R1 is an immunomodulatory protein identified from a gastric bacterium that protects against allergic asthma, hay fever, atopic dermatitis, inflammatory bowel disease, as well as other allergic diseases. (Sourced from: http://genevabiotechcenter.com/wp-content/uploads/2017/10/GBC-HpVac-Investor-Leaflet-October-2017.pdf)
Mechanisms of Action: Immunomodulator
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Geneva Biotech Center
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Asthma, Allergic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|